Azelaprag (original Amgen development code AMG 986, subsequently licensed to BioAge Labs and renamed BGE-105) is a drug which is a selective, small-molecule agonist for the apelin receptor. It was originally developed as a potential treatment for heart failure and has subsequently been investigated for other applications such as obesity and muscle wasting in elderly or bed-bound patients.